

## Lei Li

Lei Li is the Managing Partner of Sidley's Shanghai and Beijing offices, and he splits his time and practice between these two offices. Lei Li advises clients on a broad range of regulatory, compliance and government enforcement matters in China, with a particular focus on the life sciences industry, and is one of the most accoladed legal practitioners in China in his areas of practice.

Lei Li has extensive experience in all types of anti-corruption compliance and investigation matters in China. Representing both multinational companies and local Chinese companies, he has handled a large number of government anti-corruption inquiries and investigations, including those conducted by the U.S. regulators (i.e., the U.S. Department of Justice and the U.S. Securities and Exchange Commission) under the U.S. Foreign Corrupt Practices Act (FCPA), as well as those conducted by Chinese administrative enforcement authorities and criminal prosecution authorities. He also has worked extensively on internal anti-corruption risk assessments, audits and investigations for clients in China, and anti-corruption due diligence reviews in M&A transactions.

Lei Li is an experienced antitrust lawyer, and has practiced antitrust law in China since the passage of China's Anti-monopoly Law in 2008. Lei Li has focused his antitrust practice on regulatory compliance, internal investigations and government investigations. Particularly, he has handled high-stake antitrust inquiries and investigations launched by the central and provincial antitrust authorities in China, primarily in the pharmaceutical and medical device sector, where he was noted as a "pragmatic" lawyer with "good connections and experience in the healthcare industry."

In the life sciences field, Lei Li is the co-head of Sidley Austin's nationally leading China Life Sciences Practice, which has set the record of winning the "Band 1" ranking of *Chambers Asia Pacific* in the "China Life Science" category fourteen years in a row ever since its inception (2008 to 2022). For over a decade, Lei Li has advised multinational and local Chinese pharmaceutical and medical device companies on matters across the full spectrum of the industry, and has handled some of the largest and most representative matters in the industry in China in the last decade.